Efficacy and safety of Tibetan medicine Qingpeng ointment for patients with acute gouty arthritis

Not Applicable

Completed

• Conditions: Acute gouty arthritis; Musculoskeletal Diseases; Idiopathic gout

• Registration Number: ISRCTN34355813
• Lead Sponsor: Beijing University of Chinese Medicine

Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35549757/ (added 16/05/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38178115/ (added 08/01/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-25
• Study Completion: 2022-01-31
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 203

Inclusion Criteria

1. Patients who meet the ACR (American College of Rheumatology)/EULAR (European League Against Rheumatism) gout classification criteria
2. Patients with joint pain intensity score (VAS, 0-10 points) =3 points
3. Patients with an acute flare of gout, the time from the onset to the visit to hospital should not exceed 1 week
4. Patients aged between 18 to 65 years old
5. Patients who are volunteer to participate in the study and sign the informed consent

Exclusion Criteria

1. Patients who also suffer from other types of arthritis
2. Patients who are allergic to the study drugs (Qingpeng Ointment, DSSRT)
3. Patients suffering from severe cardiovascular, cerebrovascular, liver, and kidney diseases
4. Patients suffering from mental diseases and senile dementia
5. Women during pregnancy and lactation
6. Patients with skin ulceration at the affected joint(s)
7. Patients who have newly added uric acid-lowering drugs for any reason in the past week
8. Patients who participate in other clinical trials at the same time

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Joint pain measured using a visual analogue scale (VAS, 0-10 points) at baseline, every day during treatment, and after treatment<br>2. Joint swelling:<br>2.1. The width and thickness of each affected joint are measured using vernier calipers (brand: Ruineng, model: NR0139) at baseline, every day during treatment, and after treatment<br>2.2. Joint swelling measured using a visual analogue scale (VAS, 0-10 points) at baseline, every day during treatment, and after treatment